LifeSci Capital Initiates Coverage of VBL Therapeutics

Conducting a Pivotal Phase III Trial in Recurrent Glioblastoma; Report Available here: http://www.lifescicapital.com/equity-research/vbl-therapeutics/

NEW YORK, NY / ACCESSWIRE / August 21, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of VBL Therapeutics (NasdaqGM: VBLT), a clinical stage biotechnology company developing treatments for cancer using its Vascular Targeting System (VTS(TM)) technology for therapeutic gene delivery. The first patient was recently enrolled in a pivotal Phase III clinical trial for recurrent glioblastoma (GBM), which is supported by encouraging survival results in Phase II. Interim results from the trial are expected in the second half of 2016. VBL is also conducting clinical trials in ovarian and thyroid cancers, with data from both trials expected in 2015.

VBL Therapeutics’ lead candidate is VB-111, a targeted anti-angiogenic therapy in development for numerous types of cancer. VB-111 is based on the Company’s VTS platform technology, which uses an adenovirus vector to deliver a selectively activated gene that induces the apoptosis of angiogenic endothelial cells. The virus contains a promoter that is specifically activated in angiogenic endothelial cells and drives expression of a cell death gene. This can be thought of as a next generation approach complementary to the well-known vascular endothelial growth factor (VEGF) inhibitors such as Roche/Genentech’s (VTX: ROG.VX) Avastin (bevacizumab), but perhaps more broadly applicable since it is not dependent on a specific factor. VB-111 is in development for recurrent glioblastoma (GBM), ovarian cancer, and thyroid cancer. GBM is the lead clinical program, and a pivotal trial is underway.

In a 33 page Initiation Report LifeSci Capital explains the clinical data supporting a Phase III program with VB-111 in recurrent glioblastoma and the potential market opportunity, as well as VBL Therapeutics’ clinical data in ovarian and thyroid cancers.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on VBL Therapeutics as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 431475